DCLK1-IN-2 (compound I-5) is a potent DCLK1 inhibitor with an IC50?of?171.3? nM. DCLK1-IN-2 shows remarkable antiproliferative effects on SW1990?cell lines (IC50?of?0.6?μM) and in vivo antitumor potency[1].
References
[1] Yuepeng Chen, et al. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer. European Journal of Medicinal Chemistry. 7 October 2023, 115846.
